当前位置： SCI文献检索 > ADVANCES IN THERAPY期刊下所有文献 > Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).

Abstract：

:Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1 (PD-L1) antibodies, showing, in several cancer patients, an increased progression-free survival and overall survival compared with classical chemotherapy. As recently shown by several studies, the PD-L1 expression levels in tumors may offer a selection criterion for patients to predict their immunotherapy response. In particular, NSCLC patients with high tumor PD-L1 levels (proportional score ≥ 50% for first-line therapy and ≥ 1% for second-line treatment, respectively) showed better response rates to immunotherapy and longer survival in first-line therapy compared with conventional chemotherapy. PD-L1, whose expression is evaluated by using immunohistochemistry analysis, is currently the only biomarker approved for clinical use in the first- and second-line monotherapy setting and therefore plays a central role in treatment decision-making for patients with advanced NSCLC. In this review we will discuss the key role of PD-L1 as a predictive biomarker of response to pembrolizumab therapy in NSCLC patients by describing the appropriate techniques and methodologies for immunohistochemical evaluation of PD-L1 expression and providing an overview of the clinical studies supporting its predictive significance.

journal_name

Adv Ther

journal_title

Advances in therapy

authors

Incorvaia L,Fanale D,Badalamenti G,Barraco N,Bono M,Corsini LR,Galvano A,Gristina V,Listì A,Vieni S,Gori S,Bazan V,Russo A

doi

10.1007/s12325-019-01057-7

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

2600-2617

issue

10

eissn

0741-238X

issn

1865-8652

pii

10.1007/s12325-019-01057-7

journal_volume

36

pub_type

杂志文章,评审

相关文献

ADVANCES IN THERAPY文献大全
  • Totally implantable venous access devices via subclavian vein: a retrospective study of 368 oncology patients.

    abstract：:Totally implantable catheters and totally implantable venous access devices (TIVADs) represent a valid method of administering long-term chemotherapy. TIVADs have several advantages over other methods of venous access: they are easy to implant under local anesthesia, they cause less discomfort for patients, and they c...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/BF02850046

    authors： Ozyuvaci E,Kutlu F

    更新日期：2006-07-01 00:00:00

  • Long-term allergen-specific immunotherapy correlates with long-term allergen-specific immunological tolerance.

    abstract：INTRODUCTION:One method of treatment for allergic diseases is allergen-specific immunotherapy (SIT). The clinical efficacy of SIT in pollen-induced allergic rhinitis has been demonstrated in several controlled clinical trials. There is no consensus about the protective effect of SIT. In this study, we evaluated the cor...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-008-0004-3

    authors： Ali I,Goksal K,Ozan B,Gulsen D

    更新日期：2008-01-01 00:00:00

  • Can antiemetics really relieve pain?

    abstract：:The analgesic properties of 2 antiemetic agents--metoclopramide and ondansetron--were investigated in studies which showed that metoclopramide may decrease postoperative opioid requirements, but the analgesic effect of ondansetron is controversial. The postoperative effects of metoclopramide and ondansetron on pain in...

    journal_title：Advances in therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/BF02850080

    authors： Derbent A,Uyar M,Demirag K,Uyer M,Kurtoglu E,Goktay A

    更新日期：2005-07-01 00:00:00

  • Susceptibility to various oral antiseptics of Porphyromonas gingivalis W83 within a biofilm.

    abstract：:The origin of chronic periodontal disease is strongly related to the nature and physiology of the subgingival bacterial biofilm, of which Porphyromonas gingivalis is a main protagonist. This study was conducted in vitro, to test the susceptibility of the W83 strain of P gingivalis to several oral antiseptics, bearing ...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/BF02877764

    authors： Bercy P,Lasserre J

    更新日期：2007-11-01 00:00:00

  • Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.

    abstract：:Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis exhibit a progressive clinical phenotype. These chronic progressive fibrosing ILDs have a variety of underlying diseases, and their prevalence is currently unknown. Here we carry out the first systematic review of literature ...

    journal_title：Advances in therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s12325-020-01578-6

    authors： Olson A,Hartmann N,Patnaik P,Wallace L,Schlenker-Herceg R,Nasser M,Richeldi L,Hoffmann-Vold AM,Cottin V

    更新日期：2020-12-14 00:00:00

  • Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer.

    abstract：INTRODUCTION:Accumulating studies indicate that melatonin is a natural oncostatic agent capable of mediating the influence of the psychoneuroendocrine system on cancer growth. Although there is increasing evidence to show that the pineal gland may play a role in human non-small cell lung cancer (NSCLC), there is uncert...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-009-0068-8

    authors： Hu S,Shen G,Yin S,Xu W,Hu B

    更新日期：2009-09-01 00:00:00

  • Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.

    abstract：:The article "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA", written by Pierre Johansen, Barnaby Hunt, Neeraj N. Iyer, Tam Dang-Tan, Richard F. Pollock was originally published...

    journal_title：Advances in therapy

    pub_type： 已发布勘误

    doi：10.1007/s12325-019-00945-2

    authors： Johansen P,Hunt B,Iyer NN,Dang-Tan T,Pollock RF

    更新日期：2019-05-01 00:00:00

  • Vasopressor-Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review.

    abstract：:Shock is a serious acute circulatory failure leading to inadequate oxygen delivery to the cells. Its treatment is mainly based on circulating fluid optimization, and vasopressors to provide an adequate mean arterial pressure and microcirculatory flow. Norepinephrine is the drug of choice, but high dosages may be respo...

    journal_title：Advances in therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s12325-020-01422-x

    authors： Puntillo F,Giglio M,Pasqualucci A,Brienza N,Paladini A,Varrassi G

    更新日期：2020-09-01 00:00:00

  • The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

    abstract：INTRODUCTION:New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin's lymphoma, and...

    journal_title：Advances in therapy

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s12325-017-0522-y

    authors： Gulácsi L,Brodszky V,Baji P,Rencz F,Péntek M

    更新日期：2017-05-01 00:00:00

  • Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.

    abstract：INTRODUCTION:The 1100delC CHEK2 allele has been associated with a 1.4-to 4.7-fold increased risk of breast cancer in women carrying this mutation. Our study investigated the frequency of this allele in a Chinese population. METHODS:Using touchdown polymerase chain reaction, we sequenced the CHEK2.1100delC mutation in ...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-008-0057-3

    authors： Chen W,Yurong S,Liansheng N

    更新日期：2008-05-01 00:00:00

  • Retrospective estimate of the nursing cost of autonomy impairment and cost benefit in clinical trials: feasibility and application of piracetam in demented elderly patients.

    abstract：:The aims of this study were to determine whether the nursing costs of functional disability could be assessed retrospectively and, if so, whether this method was sensitive enough to show the influence of a treatment on economic costs. Four studies were available for this purpose: three randomized, double-blind, place...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：

    authors： Vlietinck R,Van Loon H,Van de Broele H,Tormans G

    更新日期：1993-09-01 00:00:00

  • Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

    abstract：:In the last few years, immunotherapy has transformed the way we treat solid tumors, including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable responses and long-term survival benefit has been experienced by many cancer patients, with favorable toxicity profiles of immunotherapeutic agents relati...

    journal_title：Advances in therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s12325-019-01051-z

    authors： Arora S,Velichinskii R,Lesh RW,Ali U,Kubiak M,Bansal P,Borghaei H,Edelman MJ,Boumber Y

    更新日期：2019-10-01 00:00:00

  • Dorsal root ganglion: the target of acupuncture in the treatment of asthma.

    abstract：:Recently, high levels of neurotrophic factors have been found in bronchial asthma; these factors include nerve growth factor, brain-derived neurotrophic factor, and leukemia inhibitory factor, among others. Neurotrophic factors are first synthesized in bronchial epithelial cells, immune cells, and other cells in the a...

    journal_title：Advances in therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF02848784

    authors： Feng JT,Hu CP,Li XZ

    更新日期：2007-05-01 00:00:00

  • Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers.

    abstract：INTRODUCTION:To assess the risk factors associated with regorafenib-related adverse events (AEs) in metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors (GIST). We also evaluated different measures of combatting AEs and their success rate to aid physicians in early identification and management of re...

    journal_title：Advances in therapy

    pub_type： 杂志文章,meta分析

    doi：10.1007/s12325-019-01013-5

    authors： Xie G,Gong Y,Wu S,Li C,Yu S,Wang Z,Chen J,Zhao Q,Li J,Liang H

    更新日期：2019-08-01 00:00:00

  • Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.

    abstract：INTRODUCTION:Fixed-combination intraocular pressure (IOP)-lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versu...

    journal_title：Advances in therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s12325-014-0168-y

    authors： Gandolfi SA,Lim J,Sanseau AC,Parra Restrepo JC,Hamacher T

    更新日期：2014-12-01 00:00:00

  • Assessing thrombosis risk in patients with idiopathic, diabetic, and postsurgical gastroparesis.

    abstract：:Patients with severe gastrointestinal motility disorders are often found to have intravenous access clots or deep venous thrombosis. It has previously been reported that many patients who have intravenous access thrombosis have concomitant thrombotic risk factors. In this study, the goal was to determine the underlyin...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/BF02850315

    authors： Lobrano A,Blanchard K,Rock W,Johnson W,Schmieg B,Borman K,Araghizadeh F,Minocha A,Abell TL

    更新日期：2006-09-01 00:00:00

  • HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.

    abstract：INTRODUCTION:Claims data (IBM MarketScan Commercial and MarketScan Medicare Supplemental databases) from June 30, 2011 to September 30, 2017 were used to evaluate the cost impact of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in this retrospective cohort study. METHODS:The p...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-020-01283-4

    authors： Sussell JA,Sheinson D,Wu N,Shah-Manek B,Seetasith A

    更新日期：2020-04-01 00:00:00

  • Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.

    abstract：INTRODUCTION:This retrospective study evaluates the efficacy of palliative chemotherapy with a modified docetaxel, cisplatin, 5-fluorouracil (5-FU; "TPF" regimen) regimen (mTPF; reduced doses of docetaxel, cisplatin, and 5-FU with reduction of intravenous 5-FU from 4 days to 2 days) in Asian patients with recurrent and...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-011-0085-2

    authors： Lin JT,Lai GM,Chang TH,Liu MT,Bi CP,Wang JW,Chen MK

    更新日期：2012-01-01 00:00:00

  • Anterior Chamber Inflammation After Cataract Surgery: A Randomized Clinical Trial Comparing Bromfenac 0.09% to Dexamethasone 0.1.

    abstract：PURPOSE:To compare the efficacy of bromfenac 0.09% and dexamethasone 0.1% in the treatment of anterior chamber inflammation after uncomplicated cataract surgery. METHODS:Seventy-six patients with senile cataracts and no other ocular comorbidities who underwent uneventful phacoemulsification were randomized 1:1 to rece...

    journal_title：Advances in therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s12325-019-01076-4

    authors： Coassin M,De Maria M,Mastrofilippo V,Braglia L,Cimino L,Sartori A,Fontana L

    更新日期：2019-10-01 00:00:00

  • Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.

    abstract：INTRODUCTION:Randomized controlled trials and real-world data from the USA have shown similar glycemic control with insulin glargine 300 U/ml (Gla-300) and insulin glargine 100 U/ml (Gla-100) and reduced hypoglycemia risk with Gla-300. This real-world study describes the efficacy and safety of Gla-300 and Gla-100 in pa...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-020-01436-5

    authors： Escalada J,Bonnet F,Wu J,Bonnemaire M,Gupta S,Cambron-Mellott JM,Nicholls C,Müller-Wieland D

    更新日期：2020-09-01 00:00:00

  • Dysfunctional Coagulation in COVID-19: From Cell to Bedside.

    abstract：:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin-converting enzyme 2 (ACE2) widely expressing in arterial and venous endothelial cells and arterial smooth muscle cells has been identified as a functional rec...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-020-01399-7

    authors： Wang J,Saguner AM,An J,Ning Y,Yan Y,Li G

    更新日期：2020-07-01 00:00:00

  • Outcome Measures of Adjustable Transobturator Male System with Pre-attached Scrotal Port for Male Stress Urinary Incontinence After Radical Prostatectomy: A Prospective Study.

    abstract：INTRODUCTION:The objective of this study was to report outcome measures with third-generation pre-attached scrotal port adjustable transobturator male system (ATOMS) for male stress urinary incontinence (SUI) after radical prostatectomy. METHODS:A prospective open study was conducted on consecutive patients. Evaluatio...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-017-0528-5

    authors： Angulo JC,Arance I,Esquinas C,Dorado JF,Marcelino JP,Martins FE

    更新日期：2017-05-01 00:00:00

  • Revisiting Existing Evidence of Corneal Endothelial Progenitors and Their Potential Therapeutic Applications in Corneal Endothelial Dysfunction.

    abstract：PURPOSE:A recent successful clinical trial demonstrated that a less invasive cell-injection procedure is a viable medical modality for treating corneal endothelial dystrophy. This medical advance still relies on human corneal endothelial cell (HCEC) sources derived from rare cornea donations. The progenitor of the corn...

    journal_title：Advances in therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s12325-020-01237-w

    authors： Meir YJ,Chen HC,Chen CC,Ma HD

    更新日期：2020-03-01 00:00:00

  • Low Level Laser Therapy in Knee Osteoarthritis: A Narrative Review.

    abstract：:Knee osteoarthritis (KOA) is the most common musculoskeletal disorder, especially in middle up to old age. KOA also results in many complications like changes in gait. Nowadays, changes in lifestyle and the reduced physical activity make people more vulnerable to KOA. Therefore, considering the increasing prevalence o...

    journal_title：Advances in therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s12325-020-01415-w

    authors： Ganjeh S,Rezaeian ZS,Mostamand J

    更新日期：2020-08-01 00:00:00

  • Enhancement of Retinal Function and of Neural Conduction Along the Visual Pathway Induced by Treatment with Citicoline Eye Drops in Liposomal Formulation in Open Angle Glaucoma: A Pilot Electrofunctional Study.

    abstract：INTRODUCTION:To evaluate the retinal function and the relative neural conduction along the visual pathway after treatment with citicoline in liposomal formulation (CLF) eye drops in patients with open angle glaucoma (OAG). METHODS:Twelve OAG patients (mean age ± standard deviation 52.58 ± 11.39 years, intraocular pres...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-019-0897-z

    authors： Parisi V,Oddone F,Roberti G,Tanga L,Carnevale C,Ziccardi L,Manni G

    更新日期：2019-04-01 00:00:00

  • Type 2 Diabetes Mellitus Patients' Healthcare Costs Related to Inpatient Hospitalizations: A Retrospective Administrative Claims Database Study.

    abstract：INTRODUCTION:Diabetes-related healthcare costs are increasing in the United States, with inpatient hospitalization the largest component of medical expenditures. The aims of this study were to characterize hospitalized type 2 diabetes mellitus (T2DM) patients, understand the relationship between hospitalization and hea...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-015-0223-3

    authors： Saundankar V,Ellis J,Allen E,DeLuzio T,Moretz C,Meah Y,Suehs B,Bouchard J

    更新日期：2015-07-01 00:00:00

  • Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis.

    abstract：:This multicenter, double-masked, randomized, parallel-group study compared the efficacy and safety of ketorolac tromethamine 0.5% ophthalmic solution with levocabastine 0.05% and ketorolac tromethamine vehicle in patients with seasonal allergic conjunctivitis. One drop of ketorolac, levocabastine, or vehicle was insti...

    journal_title：Advances in therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF02854842

    authors： Donshik PC,Pearlman D,Pinnas J,Raizman MB,Tauber J,Tinkelman D,Walters TR

    更新日期：2000-03-01 00:00:00

  • Comparative Analyses of Pharmaceuticals or Food Supplements Containing Chondroitin Sulfate: Are Their Bioactivities Equivalent?

    abstract：INTRODUCTION:Oral supplementation of chondroitin sulfate (CS) and glucosamine (GlcN), symptomatic slow-acting molecules, is recommended by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and Musculoskeletal Diseases (ESCEO) and other European Union (EU) guidelines for the restorati...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-019-01064-8

    authors： Stellavato A,Restaino OF,Vassallo V,Finamore R,Ruosi C,Cassese E,De Rosa M,Schiraldi C

    更新日期：2019-11-01 00:00:00

  • Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes.

    abstract：:The lipid triad is the association of small, dense (sd) low-density lipoprotein (LDL), low high-density lipoprotein (HDL), and hypertriglyceridemia, all of which play a role in coronary artery disease in patients with type 2 diabetes. Although statins have demonstrated clear positive effects on cardiovascular morbidit...

    journal_title：Advances in therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/BF02849947

    authors： Bevilacqua M,Righini V,Barrella M,Vago T,Chebat E,Dominguez LJ

    更新日期：2005-11-01 00:00:00

  • Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.

    abstract：INTRODUCTION:The aim of this study was to investigate whether the efficacy of liraglutide observed in randomized controlled trials translates into therapeutic benefits in the French population during routine clinical practice. METHODS:This observational, prospective, multicenter study included 3152 adults with type 2 ...

    journal_title：Advances in therapy

    pub_type： 杂志文章

    doi：10.1007/s12325-015-0245-x

    authors： Gautier JF,Martinez L,Penfornis A,Eschwège E,Charpentier G,Huret B,Madani S,Gourdy P

    更新日期：2015-09-01 00:00:00